DNA
Price
$12.72
Change
+$0.06 (+0.47%)
Updated
Jul 3 closing price
Capitalization
744.53M
IMRX
Price
$3.45
Change
-$0.14 (-3.90%)
Updated
Jul 3 closing price
Capitalization
124.15M
31 days until earnings call
Interact to see
Advertisement

DNA vs IMRX

Header iconDNA vs IMRX Comparison
Open Charts DNA vs IMRXBanner chart's image
Ginkgo Bioworks Holdings
Price$12.72
Change+$0.06 (+0.47%)
Volume$1.4M
Capitalization744.53M
Immuneering
Price$3.45
Change-$0.14 (-3.90%)
Volume$908.55K
Capitalization124.15M
DNA vs IMRX Comparison Chart in %
Loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNA vs. IMRX commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Hold and IMRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (DNA: $12.72 vs. IMRX: $3.45)
Brand notoriety: DNA and IMRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 112% vs. IMRX: 64%
Market capitalization -- DNA: $744.53M vs. IMRX: $124.15M
DNA [@Biotechnology] is valued at $744.53M. IMRX’s [@Biotechnology] market capitalization is $124.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whileIMRX’s FA Score has 0 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • IMRX’s FA Score: 0 green, 5 red.
According to our system of comparison, DNA is a better buy in the long-term than IMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 6 TA indicator(s) are bullish while IMRX’s TA Score has 4 bullish TA indicator(s).

  • DNA’s TA Score: 6 bullish, 4 bearish.
  • IMRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DNA is a better buy in the short-term than IMRX.

Price Growth

DNA (@Biotechnology) experienced а +32.36% price change this week, while IMRX (@Biotechnology) price change was +8.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

IMRX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($745M) has a higher market cap than IMRX($124M). IMRX YTD gains are higher at: 56.818 vs. DNA (29.532). IMRX has higher annual earnings (EBITDA): -63.85M vs. DNA (-387.59M). DNA has more cash in the bank: 517M vs. IMRX (35.9M). IMRX has less debt than DNA: IMRX (4.08M) vs DNA (435M). DNA has higher revenues than IMRX: DNA (237M) vs IMRX (0).
DNAIMRXDNA / IMRX
Capitalization745M124M601%
EBITDA-387.59M-63.85M607%
Gain YTD29.53256.81852%
P/E RatioN/AN/A-
Revenue237M0-
Total Cash517M35.9M1,440%
Total Debt435M4.08M10,654%
TECHNICAL ANALYSIS
Technical Analysis
DNAIMRX
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
Momentum
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
86%
MACD
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 5 days ago
87%
Declines
ODDS (%)
Bearish Trend 24 days ago
87%
Bearish Trend 24 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
Aroon
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RAFI3.280.01
+0.31%
Regency Affiliates, Inc.
MITEF18.20N/A
N/A
Mitsubishi Estate Co. Ltd.
PPRQF9.74N/A
N/A
Choice Properties Real Estate Invt Trust
FPLPF0.75N/A
N/A
VANQUIS BKG GROUP PLC
TLGUF11.22N/A
N/A
TLGY Acquisition Corporation

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
+0.47%
CRSP - DNA
54%
Loosely correlated
+0.97%
ABCL - DNA
51%
Loosely correlated
+1.33%
RXRX - DNA
50%
Loosely correlated
+1.15%
NTLA - DNA
48%
Loosely correlated
+0.09%
ABSI - DNA
47%
Loosely correlated
+2.97%
More

IMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with NUVL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRX
1D Price
Change %
IMRX100%
-3.90%
NUVL - IMRX
37%
Loosely correlated
-0.02%
SRRK - IMRX
31%
Poorly correlated
+1.24%
ENTBF - IMRX
31%
Poorly correlated
N/A
INSM - IMRX
30%
Poorly correlated
-0.45%
DNA - IMRX
29%
Poorly correlated
+0.47%
More